Research graph
References from Regional practice differences significantly affect the benefit of post-HCT gilteritinib in FLT3-ITD AML. Local targets link to admitted publications; unresolved targets remain external evidence.
Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3
10.1200/jco.23.02474 · 2024 · External reference
Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis
10.1200/jco.2011.36.9868 · 2012 · External reference
Unrelated or haploidentical allogeneic hematopoietic cell transplantation in second complete remission for acute myeloid leukemia-Improved outcomes over time: a European Society for Blood and Marrow Transplantation Acute Leukemia Working Party study
10.1002/cncr.34843 · 2023 · External reference
A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations
10.1182/bloodadvances.2018015925 · 2018 · External reference
Assessment of minimal residual disease in standard-risk AML
10.1056/nejmoa1507471 · 2016 · External reference
Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia
10.1200/jco.2003.04.036 · 2003 · External reference
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
10.1182/blood.2022016867 · 2022 · External reference
FLT3 inhibitors added to induction therapy induce deeper remissions
10.1182/blood.2019002180 · 2020 · External reference
Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial
10.1016/s0140-6736(23)00464-6 · 2023 · External reference
Allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia with 11q23 abnormality: a retrospective study of the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT)
10.1007/s00277-018-3419-1 · 2018 · External reference
Effect of allogeneic HCT from unrelated donors in AML patients with intermediate- or poor-risk cytogenetics: a retrospective study from the Japanese Society for HCT
10.1007/s00277-020-04261-6 · 2020 · External reference
Comparable outcomes after alternative and matched sibling donor hematopoietic stem cell transplantation and the role of molecular measurable residual disease for acute myeloid leukemia in elderly patients
2021 · External reference
Clinical outcomes and treatment patterns in adults with FLT3-ITD(mut+) acute myeloid leukemia undergoing allogeneic hemopoietic cell transplantation in the United States and Canada
2024 · External reference
Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation
10.1056/nejmoa1614359 · 2017 · External reference
FLT3-ITD measurable residual disease from the QuANTUM-First trial
10.1182/bloodadvances.2025016444 · 2026 · External reference
Quizartinib in newly diagnosed patients with FLT3-ITD–positive AML who received maintenance therapy in QuANTUM-First
10.1182/bloodadvances.2025017738 · 2026 · External reference
Impact of transplant conditioning, NPM1 mutations, and measurable residual disease in FLT3-ITD acute myeloid leukemia
10.1182/bloodadvances.2025016306 · 2025 · External reference
